Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.

A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Matsui, K., Masuda, N., Fukuoka, M., Yana, T., Hirashima, T., Komiya, T., Kobayashi, M., Kawahara, M., Atagi, S., Ogawara, M., Negoro, S., Kudoh, S., Furuse, K.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 1998
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2150367/
https://ncbi.nlm.nih.gov/pubmed/9667675
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky